Bastos-Oreiro, M.; de las Heras, A.; Presa, M.; Casado, M.A.; Pardo, C.; MartÃn-Escudero, V.; Sureda, A.
Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain. Cancers 2022, 14, 538.
https://doi.org/10.3390/cancers14030538
AMA Style
Bastos-Oreiro M, de las Heras A, Presa M, Casado MA, Pardo C, MartÃn-Escudero V, Sureda A.
Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain. Cancers. 2022; 14(3):538.
https://doi.org/10.3390/cancers14030538
Chicago/Turabian Style
Bastos-Oreiro, Mariana, Ana de las Heras, MarÃa Presa, Miguel A. Casado, Carlos Pardo, Victoria MartÃn-Escudero, and Anna Sureda.
2022. "Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain" Cancers 14, no. 3: 538.
https://doi.org/10.3390/cancers14030538
APA Style
Bastos-Oreiro, M., de las Heras, A., Presa, M., Casado, M. A., Pardo, C., MartÃn-Escudero, V., & Sureda, A.
(2022). Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain. Cancers, 14(3), 538.
https://doi.org/10.3390/cancers14030538
